Thus, in the light of our and some other author’s results, we postulate that BCL-2 expression may be one of the surrogate markers allowing distinguishing TN BC subtypes with different sensitivity to ATC; however, this supposition requires confirmation in further studies. This evidence concerns the gene BCL2 and breast cancer.